Price movement over the last 24 hours
ADMA Biologics Inc vs Cipher Mining Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Cipher Mining Inc trades at $21.05 (market cap $8.41B). The key difference: Cipher Mining Inc is far larger — about 3.9× ADMA Biologics Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CIFR | |
|---|---|---|
Market Cap | $2.13B | $8.41B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $29.18 |
52-Week Low | $7.60 | $4.72 |
Enterprise Value | $2.20B | $12.45B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CIFR trades at $21.73, up 8.43% today but remains in a bearish technical trend. The company is transitioning from Bitcoin mining to AI data center operations, with $11.4B in contracted lease revenue from AWS and Fluidstack. Despite strong analyst support (13 buy ratings), fundamentals show deep losses with -427.79% net margin and negative cash flow from operations.
The investment case hinges on successful execution of the AI infrastructure pivot, with revenue expected to ramp from 2027. Key risks include high valuation multiples, negative profitability, and execution challenges in data center deployment. The consensus price target of $31.61 suggests 45% upside if the transition succeeds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →